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Sepsis is characterized by overlapping phases of excessive in-
flammation temporally aligned with an immunosuppressed state,
defining a complex clinical scenario that explains the lack of
successful therapeutic options. Here we tested whether the
formyl-peptide receptor 2/3 (Fpr2/3)—ortholog to human FPR2/
ALX (receptor for lipoxin A4)—exerted regulatory and organ-
protective functions in experimental sepsis. Coecal ligature and
puncture was performed to obtain nonlethal polymicrobial sepsis,
with animals receiving antibiotics and analgesics. Clinical symp-
toms, temperature, and heart function were monitored up to 24 h.
Peritoneal lavage and plasma samples were analyzed for proinflam-
matory and proresolving markers of inflammation and organ dys-
function. Compared with wild-type mice, Fpr2/3−/− animals ex-
hibited exacerbation of disease severity, including hypothermia
and cardiac dysfunction. This scenario was paralleled by higher levels
of cytokines [CXCL1 (CXC receptor ligand 1), CCL2 (CC receptor ligand
2), and TNFα] as quantified in cell-free biological fluids. Reduced
monocyte recruitment in peritoneal lavages of Fpr2/3−/− animals
was reflected by a higher granulocyte/monocyte ratio. Monitoring
Fpr2/3−/− gene promoter activity with a GFP proxy marker
revealed an over threefold increase in granulocyte and monocyte
signals at 24 h post-coecal ligature and puncture, a response me-
diated by TNFα. Treatment with a receptor peptido-agonist con-
ferred protection against myocardial dysfunction in wild-type, but
not Fpr2/3−/−, animals. Therefore, coordinated physio-pharmaco-
logical analyses indicate nonredundant modulatory functions for
Fpr2/3 in experimental sepsis, opening new opportunities to ma-
nipulate the host response for therapeutic development.
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Sepsis is a clinical syndrome expression of the host reactionto pathogen invasion, as a consequence of either direct dis-
semination into the bloodstream or postsurgical trauma and
gut ischemia/reperfusion-mediated pathogen translocation. The
complexity of sepsis is due to multiple local and systemic immune
responses that involve release of soluble mediators such as cyto-
kines, bioactive lipid mediators, and cell stress markers, leading to
multiple organ failure and ultimately death (1). Originally believed
to result exclusively from an overzealous inflammatory response
(e.g., cytokine storm), the lack of efficacy of anticytokine therapy
in several clinical trials demonstrated that the pathogenesis of
sepsis is complex. Notwithstanding the difficulty in clinical cases to
establish the beginning of the infection (and the temporal re-
cruitment of failing organs), it is now appreciated that the systemic
inflammatory response syndrome (SIRS) can overlap with a com-
pensatory anti-inflammatory response syndrome (CARS) (2).
Immunosuppression associated with CARS may explain the fail-
ure of classical anti-inflammatory strategies in patients (3, 4).
The acute inflammatory reaction against pathogens is in many
cases successful, leading to healing and recovery of biological
function. To achieve this end point, specific mediators and
pathways of endogenous protection must be engaged by the host
to promote what is now referred to as “resolution of in-
flammation” (5). Proresolving mediators share a set of properties
that are emerging as paradigmatic (6); these include modulation
of immune cell recruitment [inhibition of polymorphonuclear
(PMN) migration and promotion of monocyte influx], augmen-
tation of phagocytosis (leading to bacteria containment), pro-
motion of apoptosis and efferocytosis, and eventually tissue/
organ repair with restoration of physiological function (6, 7). It is
perhaps for these organic and multifactorial biological actions that
proresolving mediators like the protein annexin A1 (AnxA1) and
the bioactive lipids lipoxin A4 (LXA4) and resolvin D2 exert
protection in models of experimental sepsis (8–10). Of relevance,
the receptor target for AnxA1 and LXA4 is a G protein-coupled
receptor that belongs to the formyl-peptide receptor (FPR)
family, termed FPR2/ALX. To establish the validity of FPR2/
ALX for the development of innovative therapeutic approaches,
proof-of-concept data within loss-of-function settings should
be established.
In the mouse, the human FPR2/ALX gene corresponds to two
genes, termed Fpr2 and Fpr3, which share the first of the two
exons (11). LXA4 and AnxA1 are largely inactive in a transgenic
mouse that lacks both murine genes (12) as shown in models of
acute inflammation and ischemia-reperfusion injury (12–15).
Herein we establish the patho-pharmacology of Fpr2/3 in ex-
perimental polymicrobial sepsis as a way to validate the human
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ortholog as a genuine receptor target for innovative treatments
in sepsis.
Results
Fpr2/3 Deficiency Aggravates the Host Response to Microbial Sepsis.
Induction of polymicrobial sepsis yielded worse clinical scores for
Fpr2/3−/− mice compared with WT animals: At 24 h post-coecal
ligature and puncture (CLP), WTmice developed moderate sepsis
(82%; score, ≤3), whereas 73% of Fpr2/3−/− mice recorded
a score >3, indicating severe sepsis (Fig. 1A). Rectal temper-
ature 12 h post-CLP was decreased in both genotypes, however
Fpr2/3−/− mice displayed prolonged hypothermia (Fig. 1B).
Analyses of peritoneal exudates by flow cytometry (Fig. 1C)
demonstrated increased peritoneal leukocyte recruitment 12 h
post-CLP in Fpr2/3−/− mice (Fig. S1A), largely due to increased
Ly6G+ recruitment (Fig. 1D). At 24 h post-CLP, neutrophil
numbers did not differ between genotypes, but the total number
of F4/80low monocytes was lower in Fpr2/3−/− mice (Fig. 1E).
This paucity of monocyte numbers was confirmed by immuno-
histochemistry (Iba1+ve cells; Fig. S1B) and yielded a marked
increase in neutrophil/monocyte ratio in Fpr2/3−/− mice (Fig. 1E,
Inset). Analysis of T-lymphocyte and B-lymphocyte numbers
revealed no difference between genotypes (Fig. S1 C and D).
Thus, Fpr2/3 deficiency aggravates the host response to mi-
crobial sepsis and impairs the timely resolution of peritoneal
inflammation. The augmented Ly6G+ neutrophil recruitment
observed following CLP in Fpr2/3−/− mice was not indicative of
indiscriminate higher extents of cell trafficking, as leukotriene
B4, KC [keratinocyte chemokine, also termed CXCL1 (CXC
receptor ligand 1)], and TNFα evoked similar recruitment in the
two genotypes (Fig. S2).
Soluble Mediator Generation in Fpr2/3−/− Mice. Assessment of ex-
udate cytokine levels revealed selected alterations in Fpr2/3−/−
mice with higher levels of KC, MCP-1 [monocyte chemoattractant
protein 1, also termed CCL2 (CC receptor ligand 2)], and IL-6.
TNFα, IFNγ, IL-10, and IL-17α levels incremented to a similar
degree at 12 h, yet they remained elevated at 24 h post-CLP in
Fpr2/3−/− animals (Fig. S3). In the plasma, specific cytokines were
detected, with increased levels of KC, IL-6, TNFα, and IFNγ 24 h
post-CLP in Fpr2/3−/− mice (Fig. S4). Liquid chromatography–MS/
MS (LC–MS/MS) spectroscopy allowed determination of multiple
bioactive lipids with significantly augmented levels of PGE2 and
6-keto-PGF1α in peritoneal exudates of Fpr2/3−/− mice (Table S1).
We then analyzed the presence of the Fpr2/3 agonists AnxA1
and LXA4. At the time points under observation, peritoneal
levels of AnxA1 increased more than fourfold, over sham, with
no difference between genotypes. LXA4 levels were markedly
increased in Fpr2/3−/− mice 24 h post-CLP, whereas levels were
much lower in WT animals (Fig. S5).
Fpr2/3 Absence Impairs Bacterial Clearance. As a worse outcome of
sepsis is associated with bacteremia (16) and Fpr2/3 agonists
promote bacterial phagocytosis in vitro (17), we investigated
whether Fpr2/3−/− mice displayed altered bacterial clearance in
vivo. Fig. 2 shows that Fpr2/3−/−mice exhibited higher peritoneal
bacteria content following CLP as quantified by flow cytometry
(Fig. 2 A and B and Fig. S6A), a result confirmed also through
peritoneal bacterial colony counts (Fig. S6B). Blood bacteria
counts were also elevated in Fpr2/3−/− mice (Fig. S6C).
As neutrophils were the principal cell type present in the in-
flammatory exudates of Fpr2/3−/− mice post-CLP, we in-
vestigated whether the phagocytic ability of this cell type was
compromised. Exudate neutrophils from Fpr2/3−/− mice phago-
cytosed much less Escherichia coli than WT cells (Fig. 2 C and
D). Addition of AnxA1 to WT neutrophils incremented both the
proportion of cells with internalized bacteria (Fig. 2E) and their
median fluorescence intensity (a sign for higher engulfment per
cell; Fig. 2F), effects absent in neutrophils lacking Fpr2/3. Effi-
ciency of bacteria killing was investigated next. Following 2 h of
incubation, WT exudate neutrophils (SI Methods) killed ∼13% of
phagocytized bacteria, whereas Fpr2/3−/− cells displayed minimal
bactericidal capability (Fig. 2G). Collectively, these data dem-
onstrate fundamental properties for host Fpr2/3 to manage
peritoneal bacteria infection.
Fpr2/3 Gene Modulation in Immune Cells During Sepsis. Fpr2/3−/−
mice bear an in-frame GFP reporter construct (12). Following
CLP, a ∼threefold increase in GFP signal was measured in F4/80+ve
monocytes, with >twofold in Ly6G+ neutrophils (Fig. 3A). To in-
vestigate the activating role of soluble mediators, Fpr2/3−/− perito-
neal macrophages were incubated with peritoneal lavages from CLP
WT or Fpr2/3−/− animals. At 24 h, increased GFP expression was
measured, whereas lavages from sham-operated animals were in-
active (Fig. S7A). This outcome was irrespective of genotype.
Next, macrophages were incubated with single proin-
flammatory cytokines, yet Fpr2/3 gene activation was solely in-
duced by TNFα, as shown by (i) increased GFP fluorescence
intensity (using Fpr2/3−/− cells; Fig. 3B) and (ii) elevated Fpr2/3
mRNA message in WT but not TNFα type I receptor null mac-
rophages (Fig. S7B). Similar results could be replicated in mouse
Fig. 1. Fpr2/3 deficiency aggravates response to microbial sepsis. WT and
Fpr2/3−/− mice were subjected to CLP at time 0. (A) At 24 h post-CLP, mice
were scored for the presence or absence of six different macroscopic signs of
sepsis (SI Methods). A clinical score >3 is considered as severe sepsis. Data are
from 11 mice; *P < 0.05 (Fisher’s exact test). (B) Temporal changes in rectal
temperature post-CLP in WT and Fpr2/3−/− animals. (C) Scattergrams illus-
trating neutrophil (identified as Ly6G+F4/80–) and monocyte–macrophage
(identified as Ly6G–F4/80+) positive events in peritoneal lavages from WT
and Fpr2/3−/−mice at 24 h post-CLP. (D and E) Cumulative data for peritoneal
Ly6G+ and F4/80+ cells. (Inset) Ratios of neutrophils/monocytes. Data are
mean ± SEM of six mice per genotype. ***P < 0.001 versus respective WT
value (two-way ANOVA, post hoc Tukey test).
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bone marrow-derived neutrophils (Fig. S7C). TNFα treatment of
human primary blood monocytes enhanced cell surface FPR2/
ALX receptor expression (Fig. S7D).
Cardiac Dysfunction Following Polymicrobial Sepsis Is Exacerbated by
Fpr2/3 Deficiency. The principal cause of mortality in sepsis is
organ failure, with heart, liver, and kidney being among the most
commonly affected organs (16). In our settings, CLP had no
effect on plasma creatinine and urea levels (indicative of renal
dysfunction) in WT animals, except for a transient increase in
urea levels significant at 12 h post-CLP (Fig. S8 A and B).
However, compared with WT, CLP Fpr2/3−/− mice demonstrated
a significant increase in plasma urea (12 h and 24 h post-CLP) and
creatinine (24 h time point), indications for development of acute
kidney injury (Fig. S8 A and B). For liver dysfunction, both geno-
types exhibited increased levels of plasma alanine aminotransferase
and aspartate aminotransferase markers following CLP, however
alanine aminotransferase levels augmented to a significantly greater
degree after 12 h in Fpr2/3−/− mice (Fig. S8 C and D). There was
some evidence for higher granulocyte recruitment in Fpr2/3−/−
organs, measured as myeloperoxidase (MPO) activity, albeit
modest, with an evident difference in null mouse kidney at 24 h
post-CLP (Fig. S8 E and F).
Left ventricular functionality was assessed in vivo using echo-
cardiography. Fig. 4A presents typical M-mode echocardiograms of
sham and CLP mice. Sham mice demonstrated no significant dif-
ferences in percentage ejection fraction, fractional shortening, or
fractional area change (Fig. 4 B–D) between the two genotypes. WT
CLP mice demonstrated a significant reduction in all three
parameters, indicative of impaired systolic contractility (visually
shown in Fig. 4A). Lack of Fpr2/3 exacerbated cardiac dysfunc-
tion with significant reductions in ejection fraction (–45%),
fractional shortening (–37%), and fractional area of change
(–59%) (Fig. 4 B–D). No significant differences were apparent
between the two genotypes in terms of heart rate (Fig. 4E) or
granulocyte recruitment (assessed by MPO activity; Fig. 4F).
Despite the compromised cardiac function, WT animals did not
show increased plasma levels of Troponin-I at 24 h post-CLP,
however these were elevated in Fpr2/3−/− mice, indicative of
unabated cardiac dysfunction (Fig. 4F). Finally, both Fpr2 and
Fpr1 mRNA expression was increased in WT heart tissue sam-
ples 24 h post-CLP (Fig. 4G).
Together, these data demonstrate that endogenous activation
of Fpr2/3 plays a major role in dampening dysfunction in distinct
organs during polymicrobial sepsis, with a particular efficacy in
preserving cardiac function.
Fpr2/3 Agonism Protects Against Myocardial Dysfunction. Finally, we
investigated the therapeutic potential of a stable AnxA1-based
FPR2/ALX agonist (18). Administration of CR-Ac2–50 (3 μg or
550 pmol per mouse) improved cardiac function: These pro-
tective actions were not observed in mice lacking Fpr2/3 (Fig. 5
A–C). Treatment with the peptide did not alter markers of
liver dysfunction (Fig. S9 A and B), whereas an effect on
kidney markers was evident at 24 h post-CLP. Peptide CR-Ac2–50
improved the clinical status of WT animals, again with no efficacy in
Fpr2/3−/− animals (Fig. S9C). Administration of peptide CR-Ac2–50
decreased the total number of both neutrophils and monocytes
recruited 24 h post-CLP in WT mice (Fig. S8 D–F). A tendency in
the reduction of peritoneal bacteremia was seen post–CR-Ac2–50
administration (Fig. S9G). Assessment of exudate cytokines dem-
onstrated that although IL-6, IL-1α, IFNγ, IL-17α, KC, and MCP1
content was not altered (values comparable to vehicle group), CR-
Ac2–50 decreased (∼35%) TNFα levels in WT, but not Fpr2/3−/−,
Fig. 2. Inadequate bacterial clearance in the absence of Fpr2/3. WT and
Fpr2/3−/− mice were subjected to CLP at time 0. (A) Representative flow
cytometry scattergrams illustrating bacteria (SYTO BC bacteria dye) positive
events in E. coli suspension (Left) as well as 24 h post-CLP peritoneal exu-
dates from WT and Fpr2/3−/− mice. The density of bacteria in the experi-
mental samples was determined from the ratio of bacterial to microsphere
signals. (B) Bacteria levels in peritoneal lavages from WT and Fpr2/3−/− mice.
Data are mean ± SEM of six mice. ***P < 0.001 versus correspondent WT
value (two-way ANOVA, post hoc Tukey test). (C and D) In vitro bacteria
phagocytosis by zymosan-elicited neutrophils following incubation with
pHrodo Red E. coli BioParticles for 90 min at 37 °C. (C) Bacteria phagocytosis
represented as percentage of positive cells. (D) Cell-associated fluorescence
measured as median fluorescence intensity (MFI) units. Data are mean ± SEM
of six mice. *P < 0.05 versus correspondent WT value (Student t test). (E and F)
Effect of AnxA1 (10 nM; 4 h at 37 °C) on neutrophil phagocytosis of pHrodo Red
E. coli BioParticles and cellular MFI intensity. Data are mean ± SEM of 3–4 mice
per group. *P < 0.05 versus vehicle; +P < 0.05 versus correspondent WT value
(two-way ANOVA, post hoc Tukey test). (G) Zymosan-induced peritoneal cells
were incubated with opsonized E. coli for 2 h and bactericidal activity de-
termined using a gentamicin survival assay. Data are mean ± SEM of three mice.
*P < 0.05 versus correspondent WT value (Student t test).
Fig. 3. Modulation of Fpr2/3 gene expression in immune cells during poly-
microbial sepsis. (A) Fpr2/3−/− mice, bearing an in-frame GFP reporter con-
struct, were subjected to CLP at time 0 and exudates collected at the 24 h time
point. (Left) Representative histograms showing GFP fluorescence as quanti-
fied by flow cytometry in monocytes (Mo) and neutrophils (PMN) from sham
(blue) or CLP (red) exudates. (Right) Cumulative data showing increment over
sham in cell-associated GFP. Mean ± SEM, six mice. (B) Biogel-elicited
macrophages from Fpr2/3−/− mice were incubated with the indicated cytokines
(all at 50 ng/mL) for 24 h at 37 °C before assessment of GFP fluorescence by flow
cytometry. Data are mean ± SEM of 3–4 distinct cell preparations. ***P < 0.001
versus control (one-way ANOVA, post hoc Dunnet test).











mice (Fig. S9H). Plasma levels of TNFα and IL-6 levels were also
reduced (Fig. S9 I and J).
Together, these data demonstrate that exogenous activation
of Fpr2/3 affords marked improvement of cardiac dysfunction
following sepsis, possibly consequent to modulation of the in-
flammatory response both locally and in the circulation.
Discussion
We characterize here a nonredundant endogenous pathway that
protects the host against disseminated polymicrobial sepsis.
Engagement of Fpr2/3 (mouse ortholog of human FPR2/ALX) is
crucial to enact nonredundant functions that span from cell re-
cruitment to phagocytosis, from control of soluble mediator
generation to containment of inflammation within the site,
thus preventing spreading to vital organs. The augmented im-
paired function detected in the kidney and heart is indicative
of fundamental protective properties evoked by FPR2/3, which
could be harnessed by the exogenous administration of peptide
CR-Anx2–50.
The consensus definition of sepsis as a SIRS that occurs during
infection (19) propelled the trialing of different anti-inflammatory
approaches ranging from corticosteroids (20) to neutralizing anti-
endotoxin strategies (21) and from TNFα (3, 22) to IL-1 receptor
antagonist (23). Unfortunately, none of these treatments resulted in
effectively reducing mortality; rather, in some cases, they were
detrimental (22). Therefore, sepsis remains a major clinical chal-
lenge, and the need for new treatments is urgent.
CLP, the gold standard model of sepsis, produces a poly-
microbial infection with ensuing immune, hemodynamic, and
biochemical responses that replicate those observed in patients
with sepsis (24). Older patients are more frequently affected by
sepsis, and the treatment at intensive care units is, except for
early administration of antibiotics, mostly of a supportive nature,
including vasopressor therapy and fluid replenishment (25). In
this study, we simulated these conditions by performing CLP in
8-mo-old mice treated with a large spectrum of antibiotic and
fluids (26, 27). Fpr2/3−/− mice developed longer lasting macro-
scopic signs of severe sepsis, as evident from 24 h of hypother-
mia, than WT animals.
The homeostatic functions of proresolving and tissue-protective
pathways are now emerging in several immune contexts, in-
cluding arthritis, colitis, periodontal pathologies (5), and ische-
mia/reperfusion damage (13). The complex biological functions
affected by Fpr2/3 afforded efficacy against polymicrobial sepsis
downstream of positive modulation of multiple life-saving pro-
cesses through a single receptor determinant. Indeed, the ap-
preciation that sepsis is not just SIRS but rather a complex
clinical setting with an overlapping CARS indicates that in-
novative approaches must be proposed.
There is experimental evidence that endogenous agonists of
Fpr2/3 are protective in experimental sepsis. The omega-6 de-
rivative LXA4, administered to CLP rats increases survival rates
and attenuates tissue injury (9). The omega-3 derivative resolvin
D1 improves the outcome of sepsis (28). Work from our group
has identified marked Anxa1 gene activation in experimental endo-
toxaemia, together with a higher toxic response in AnxA1−/− mice,
a phenotype rescued by exogenous application of the protein (8).
From a therapeutic perspective, a recent study conducted with
peptide WKYMVm, a panagonist at FPRs, described the control of
severe sepsis after microbial infection (29). Albeit interesting, this
study does not provide target validation to the properties of FPR2/
ALX agonists and focuses solely on the host immune response
rather than complementing it with organ functionality. These phar-
macological studies indicate a role for Fpr2/3, but the mechanism(s)
it might control in the contest of sepsis remained unexplored.
The Fpr2/3 agonists AnxA1 and LXA4 could be detected in
peritoneal infected exudates with an interesting “overshooting” of
the latter in Fpr2/3−/− mice, likely indicative of a “frustrated”
compensatory loop to dampen the exacerbated inflammatory re-
sponse. This would also suggest that LXA4 is the pivotal agonist in
these settings or, rather, that a temporal distinction for agonist
generation exists, when one compares profiles of AnxA1 and LXA4
levels in WT mice. Following detection of endogenous agonists, we
noted that a variety of host responses were altered when the Fpr2/3
axis was not engaged, pointing again to nonredundant multiple
Fig. 4. Cardiac dysfunction following polymicrobial sepsis is exacerbated by
Fpr2/3 deficiency. WT and Fpr2/3−/− mice were subjected to CLP at time
0 before analysis of cardiac function at the 24 h time point by echocardi-
ography. (A) Representative M-mode echocardiograms 24 h post-CLP or
sham from WT or Fpr2/3−/− mice. (B) Cumulative data for percentage ejec-
tion fraction measured as percent of the total amount of blood ejected in
the left ventricle with each heartbeat. (C) Cumulative data for fractional
shortening measured as percent of left ventricle internal diameters between
the diastolic and systolic phases. (D) Cumulative data for fractional area of
change measured as percent change in left ventricular cross-sectional area
between diastole and systole. (E) Myocardial MPO activity 24 h post-CLP or
sham samples from WT or Fpr2/3−/− mice. (F) Plasma troponin I levels 24 h
post-CLP or sham samples from WT or Fpr2/3−/− mice. (B–F) Mean ± SEM of
six mice. ***P < 0.001 versus corresponding sham value; +++P < 0.001 be-
tween genotypes (two-way ANOVA, post hoc Tukey test). (G) WT myocardial
Fpr1 and Fpr2 mRNA quantification by real-time PCR. Data are expressed as
fold CLP increase over sham (mean ± SEM of six mice).
Fig. 5. Fpr2/3 agonism modulates organ injury in polymicrobial sepsis. WT
and Fpr2/3−/−mice were subjected to CLP at time 0 and treated with peptide
CR-Ac2–50 1 h and 9 h postsurgery (90 μg/kg i.p.), or with vehicle (100 μL i.p.),
before being sacrificed at 24 h post-CLP. (A–C) Assessment of myocardial
dysfunction by echocardiography; mean ± SEM of six mice per group. *P <
0.05, **P < 0.01, ***P < 0.001 versus correspondent vehicle value; +++P <
0.001 between genotypes (two-way ANOVA, post hoc Tukey test).
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regulatory functions. Thus, selected changes in cytokine and che-
mokine levels were associated with augmented bioactive lipid
generations. Of interest, major differences were measured for KC
(CXCL1), MCP-1 (CCL2), and IL-6. High MCP-1 levels were
not married by an efficient monocyte influx (quite the oppo-
site), indicating the requirement for other pathways to bring in
monocytes, a crucial process for the in situ differentiation into
phagocytozing macrophages that regulate resolution (30). It is
plausible that CCR2 independent pathways might be altered.
Relevantly, LXA4 can promote nonphlogistic monocyte migra-
tion (31), and the same occurs for another Fpr2/3 ligand, the
cathelicidin LL-37 (32).
The poor recruitment of monocytes observed in Fpr2/3−/−
animals is functionally linked to a lower number of macrophages,
higher neutrophil/monocyte–macrophage ratios, and inadequate
bacterial removal. Congruently, clearance of bacteria from the
peritoneal cavity was markedly reduced in Fpr2/3−/− mice, pos-
sibly enacting a vicious circle leading to potentiation of in-
flammation and delayed resolution, as evident from the higher
cfu formation in Fpr2/3−/− peritoneal fluids. Bacteria counts
were also elevated in the circulation. Analyses of cell behavior
indicated, besides defective recruitment, a direct impairment of
phagocyte functions in Fpr2/3−/− neutrophils. Although not in
these settings, studies have demonstrated the importance of
AnxA1, LXA4, and more recently resolvin D1 in promoting
particle phagocytosis and efferocytosis by immune cells (17, 33,
34) together with ineffectiveness in cells lacking Fpr2/3 (35).
The ultimate cause of death in patients with sepsis is multiple
organ failure. Absence of Fpr2/3 was associated with major
changes in distant organ injury, with a particular effect upon
heart and kidney. An exacerbated myocardial dysfunction oc-
curred in the transgenic, as reflected by a marked profound
decrease in ejection fraction, fractional shortening, or fractional
area. Myocardial dysfunction frequently accompanies severe
sepsis (36), yet the distinctive feature of myocardial dysfunction
does not appear to be the hypoperfusion of the heart but rather
the release of circulating depressant factors, including cytokines
like TNFα (37). Indeed, high levels of cytokines quantified in
Fpr2/3−/− mice could underlie organ dysfunction: There are
indications that unabated circulating cytokines are predictive of
early mortality in sepsis (38). Some of them, like TNFα and IL-
1β, can exert a direct effect through increased expression of
inducible NO synthase (39, 40). In any case, the augmented
myocardial injury determined by Fpr2/3 absence was functional,
as evident with poor systolic pressure and pulse.
Whereas liver and lungs were mildly affected in the CLP
model, with little or no difference between the two genotypes,
different responses were quantified for the kidney parameters.
The kidney is relatively resistant, and indeed markers of injury
were not elevated in WT mice subjected to our protocol of
sepsis. In contrast, elevated urea and creatinine plasma levels
were measured in Fpr2/3−/− mice. Kidney MPO activity, an index
of granulocyte tissue recruitment, was increased in the null ani-
mal, prompting speculation that—at least in part—unchecked
inflammation could be the cause of acute kidney injury experi-
enced by Fpr2/3−/− mice. Cellular infiltrates, particularly neu-
trophils, damage tissue directly by realizing lysosomal enzymes
and superoxide-derived radicals (41). It is also plausible that the
hypotension/vasodilatation derived from impaired cardiac func-
tion could at least contribute to kidney damage.
Two sets of data merit further discussion. The first one entails
the pivotal role played by TNFα, but not other cytokines tested,
in activating the Fpr2/3 gene promoter, as demonstrated using
a combination of reporter assays ex vivo and in vitro, with
analyses in mouse and human cells. The appreciation that
proinflammatory mediators set in motion the resolution and
protective phase of inflammation is emerging (42), yet our data
solidly show this link and identify TNFα as the culprit, acting
through the type I receptor. This set of data extends previous in
vitro observations in synovial fibroblasts (43) and mouse micro-
glial cells (44). It could be speculated that failure of anti-TNFα
strategies in sepsis may, at least in part, be due to inadequate
induction of a protective pathway in the host, including AnxA1,
the agonist (8), and its receptor Fpr2/3 (this study).
The second comment relates to the pharmacological experi-
ments with CR-Ac2–50. Therapeutic delivery of this peptide,
highly selectivity for human FPR2/ALX (IC50, ∼10 nM) over
FPR1 (18), afforded marked protection. It is relevant here that
CR-Ac2–50 inhibited neutrophil trafficking while enhancing
macrophage efferocytosis in sterile inflammation (18), possessing
therefore a few of the necessary properties, as discussed above, to
elicit host protection. Control of the immune response by CR-Ac2–50
was complemented by a significant attenuation of the impair-
ment in systolic contractility. This effect can reflect an indirect
protection through reduced inflammation but also could be the
consequence of a direct protective action on the myocardium,
preserving its contractile function (45, 46). None of these biological
properties were retained in Fpr2/3−/− mice. The documented in-
crease in myocardial mRNA for Fpr1 and Fpr2 can be explored in
future investigations. These data complement recent studies con-
ducted with panagonists of formyl peptide receptors (28, 29).
In conclusion, we describe nonredundant properties of en-
dogenous Fpr2/3, the receptor determinant for agonists of the
resolution of inflammation process, in a model of polymicrobial
sepsis. This nonredundant role stems from multiple biological
functions controlled by this master receptor, which is able to set
in motion an integrated battery of host-protective effects oper-
ative both at the site of infection and in distant vital organs
(Fig. 6). Therapeutic innovation in the management of sepsis can
derive from the development of selective Fpr2/3 (and FPR2/
ALX in man) agonists, and this could include small molecules,
peptidomimetics, as well as bioactive lipid derivatives (47).
Methods
SI Methods provides an extended version of the experimental procedures.
Polymicrobial Sepsis. CLPwas performed in8-mo-oldmaleC57BL/6 or Fpr2/3GFP/GFP
(thereafter referred to as Fpr2/3−/−) mice, bearing a knocked-in gene for green
fluorescent protein (12), using a protocol that mimics clinical management in in-
tensive care units including fluid resuscitation, antibiotic therapy, and analgesia
Fig. 6. Loss of host control on polymicrobial sepsis in the absence of Fpr2/3.
The control exerted by endogenous engagement of FPR2/ALX (mimicked here by
its orthologs Fpr2/3) is dual: regulation for an optimal local reaction with proper
dealing by host immune cells with the bacteria load, and modulation of circu-
lating mediators and distant organ functionality (heart and kidney).











after surgery (27). In some experiments, mice were treated with peptide CR-
AnxA12–50. A clinical score for monitoring the health of experimental mice was
used. Animals were killed 12 or 24 h later. All animal experiments were
approved by the local Animal Use and Care Committee in accordance with
the United Kingdom Animals (Scientific Procedures) Act of 1986. Human cells
were prepared according to an approved protocol (East London & the City
Local Research Ethics Committee; no. 06/Q605/40; P/00/029).
Assessment of Cardiac Function in Vivo. Cardiac function was assessed in mice
by echocardiography (48).
Bacteria Counting. Accurate enumeration of bacteria in peritoneal lavages
was performed by flow cytometry using the SYTO BC bacteria counting kit.
Blood and peritoneal bacteria loads were also determined by growth on
a tryptic soy agar plate, as reported (10).
Peritoneal Lavage Lipid Quantification. Quantification of 6kPGF1α, TXB2, PGE2,
LxA4, LTB4, and PGD2 in peritoneal lavages was achieved by LC–MS/MS
measurements as described (49).
Neutrophil Phagocytosis and Killing Assay. Exudate neutrophils (50) were
labeled with anti-Ly6G, and phagocytosis of pH-sensitive Phrodo E. coli
bioparticles was measured by flow cytometry. Neutrophil bactericidal
activity was measured following incubation with opsonized E. coli.
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SI Methods
Animals. Male C57BL/6 or Fpr2/3GFP/GFP (thereafter referred
to as Fpr2/3−/−) mice, bearing a knocked-in gene for green
fluorescent protein (1), were maintained on a standard chow
pellet diet with free access to water and a 12-h light–dark
cycle. All animal experiments were approved by the local
Animal Use and Care Committee in accordance with the
United Kingdom Animals (Scientific Procedures) Act of 1986.
Human cells were prepared according to an approved protocol
(East London & the City Local Research Ethics Committee;
no. 06/Q605/40; P/00/029).
In Vivo Models.
Polymicrobial sepsis. Coecal ligature and puncture (CLP) was
performed in 8-mo-old male C57BL/6 or Fpr2/3−/− mice using
our published protocol that mimics clinical management in
intensive care units (2), including fluid resuscitation (Acetated
Ringer’s solution; 0.5 mL per mouse), antibiotic therapy
(Imipenem/Cilastin; 20 mg/kg body weight s.c.), and analgesia
(buprenorphine; 0.05 mg/kg body weight i.p.) at 6 h and 18 h
after surgery (2). In some experiments, mice were treated 1 and
9 h after CLP with a stable AnxA1-derived peptide, termed
CR-AnxA12–50 (3 μg per mouse i.p.), or vehicle (saline/0.01%
DMSO). Sham-operated mice underwent the same procedure
but without CLP.
A clinical score for monitoring the health of experimental mice
was used to evaluate the symptoms consistent with murine sepsis.
The maximum score of 6 comprised the presence of the following
signs: lethargy, piloerection, tremors, periorbital exudates, re-
spiratory distress, and diarrhea. Mice with a clinical score>3 were
defined as exhibiting severe sepsis, against a moderate sepsis for
a score ≤3. Mice were killed 12 or 24 h later after assessment of
cardiac function by echocardiography. Blood was collected by
cardiac puncture and peritoneal lavage fluid, and kidney and
lung tissue were also collected and stored at −80 °C for further
analysis. Plasma and peritoneal cytokine levels were determined
by cytokine beads assay (eBioscience). Peritoneal cells were
counted using Turks solution and differentiated by flow cyto-
metric analysis, as described below. Plasma was analyzed for
levels of serum creatinine, urea, aspartate aminotransferase, and
alanine transaminase (IDEXX Laboratories) for analysis.
Neutrophil phagocytosis and killing assay. Exudate neutrophils,
obtained 6 h after i.p. injection of zymosan (3), were plated in 96-
well plates at a density of 0.5 × 106 cells per well in complete
medium. pH-sensitive Phrodo E. coli bioparticles (Invitrogen)
were added to the cells. Neutrophils were labeled with anti-
Ly6G, and the number of phagocytosing cells was measured by
flow cytometry.
Neutrophil bactericidal activity was measured by incubating 2 ×
106 neutrophils with 2 × 107 opsonized E. coli for 1 h. After
infection, gentamicin (5 μg/mL) was added to the plates for 1 h,
allowing the antibiotic to kill all bacteria that were not able to
penetrate the cells and remained outside. The wells were then
washed to remove the dead bacteria. Next the neutrophils were
lysed using 0.1%Triton X-100, releasing the bacteria that pene-
trated the cells and remained alive. Lysates were then plated on
solid medium plates, and the number or viable bacteria was
determined by colony counting of live bacteria.
Bacteria counting. Accurate enumeration of bacteria in peritoneal
lavages was performed by flow cytometry using the SYTO BC
bacteria counting kit (Invitrogen) according to the manufacturer’s
instructions. Blood and peritoneal bacteria loads were also
determined by growth on tryptic soy agar plate as reported
previously (4).
Assessment of cardiac function in vivo (echocardiography). Cardiac
function was assessed in mice by echocardiography in vivo as
reported previously (5). At 24 h after CLP, anesthesia was in-
duced with 3% (vol/vol) isoflurane and maintained at 0.5–1% for
the duration of the procedure. Before assessment of cardiac
function, mice were allowed to stabilize for at least 10 min. 2D
and M-mode echocardiography images were recorded using
a Vevo-770 imaging system (VisualSonics). Percentage fractional
area change was assessed with a 2D trace of left ventricle (LV)
and was derived by 100 × (LV end-diastolic area – LV end-
systolic area) / LV end-diastolic area. The method involves
tracing the endocardial surface of the LV in the parasternal short
axis view at the level of papillary muscles. Percentage ejection
fraction (EF) and percentage fractional shortening (FS) were
calculated from the M-mode measurements of the LV internal
dimension (LVID) in the diastolic (d) and systolic (d) phase, in
the parasternal short axis view at the level of the papillary
muscles. Percentage EF was calculated using the formula: 100 ×
{[LVID (d)3 – LVID (s)3] / LVID (d)3}; percentage FS was
derived using the formula: 100 × {[LVID (d) – LVID (s)] / LVID
(d)} (2, 5, 6).
Primary Macrophage and Human Monocyte Cultures. Mice were
injected with 1 mL of 2% Bio-Gel (Bio-Rad) i.p., and 4 d later,
peritoneal lavages were harvested with 4 mL of EDTA (3 mM) in
PBS. Cells (0.5 × 106) were plated in 24-well plates in RPMI
medium 1640 containing 10% (vol/vol) FCS and 50 mg/mL of
gentamicin. After 2 h at 37 °C, nonadherent cells were washed
and adherent cells (>90% macrophages) were incubated in
RPMI 1640 1% FCS supplemented with specific cytokines (all at
50 ng/mL)—as indicated later—or vehicle. Cytokines were pur-
chased from PeproTech. In a set of experiments, TNFα type I
receptor null cells (from the colony described in ref. 7) were
prepared and compared with macrophages prepared from
C57BL/6 mice.
Primary human monocytes were extracted from the whole
blood of healthy donors using the RosetteSep negative selection
assay (Stem Cell Technologies Inc.) according to the manu-
facturer’s protocols. Cells were resuspended in RPMI medium
1640, supplemented with 0.1% BSA, 100 U/mL penicillin, and
100 μg/mL streptomycin for all assays. Extractions were per-
formed immediately before use in experiments.
Immunofluorescence Analyses. Peritoneal cells were fixed by in-
cubation with 2% formaldehyde for 15 min at room temperature,
washed, and immunostained for the monocyte/macrophage
marker protein Iba1. Briefly, after 30 min at room temperature in
10% normal goat serum containing 0.025% saponin, cells were
incubated for 1 h with a rabbit anti-mouse Iba1 polyclonal an-
tibody (1/1,000; Wako Chemicals). After washing, cells were
incubated for 30 min with AF594-conjugated goat anti-rabbit IgG
secondary antibody (1/300), before further washing and mounting
under glass coverslips using Moviol mounting agent (Sigma-
Aldrich). Cells were then examined at 20× magnification using
EVOS microscope (Life Technologies).
Biochemical Analyses.
Flow cytometry. Peritoneal cells were differentiated using anti-F4/80
(clone BM8; BioLegend), anti-Ly6G (clone 1A8; BioLegend),
anti-CD3 (clone 145–2C11; eBioscience), and anti-B220 (clone
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RA-3–6B2; BioLegend) antibodies. Fpr2/3 gene promoter activity
was quantified by the proxy marker GFP (1). Isolated human
monocytes were fixed with 2% (wt/vol) formaldehyde in 0.1 M of
PBS before immunostaining with mouse monoclonal anti-FPR2
(Genovac), followed by secondary labeling with AF488-conjugated
goat anti-mouse IgG (Invitrogen). In all cases, 20,000 events were
acquired with a FACSCalibur (Becton Dickinson) and analyzed
using FlowJo analysis software (version 9.2, Treestar Inc.).
Annexin A1 ELISA.Quantification of Annexin A1 in peritoneal lavages
was obtained by sandwich ELISA as previously described (8).
Peritoneal lavage lipid quantification. Quantification of 6kPGF1α,
TXB2, PGE2, LxA4, LTB4, and PGD2 in peritoneal lavages was
achieved by LC–MS/MS measurements as described (9, 10).
Briefly, to simultaneously separate lipids of interest and three
deuterated internal standards, LC–MS/MS analysis was per-
formed on the UHPLC (ultra high performance liquid chroma-
tography) System (Agilent LC1290 Infinity) coupled to Agilent
6460 triple quadruple MS (Agilent Technologies) equipped with
electrospray ionization operating in negative mode. Reverse-
phase UHPLC was performed using ZorBAX SB-C18 column
(2.1 mm, 50 mm, 1.8 μm) (Agilent Technologies) with a gra-
dient elution. Data were acquired in Multiple Reaction Moni-
toring mode with optimized conditions (ion optics and collision
energy). Peak detection, integration, and quantitative analysis
were done using Mass Hunter Quantitative analysis software
(Agilent Technologies). For each standard, calibration curves were
built using 10 solutions at concentrations ranging from 0.95 ng/mL
to 500 ng/mL.
Determination of MPO activity in heart, kidney, and lung tissue. Myelo-
peroxidase (MPO) activity was measured as an index of blood-
borne PMN infiltration as described (11).
Real-time PCR analysis. Total RNA from biogel-elicited macro-
phages was isolated with TRIzol reagent (Invitrogen) according
to the manufacturer’s protocol. In all cases, total RNA (1 μg) was
reverse-transcribed with random hexamer oligonucleotides and
SuperScript III (Invitrogen). Amplification was performed with
a LightCycler 480 using a SYBR Green I Master Kit (Qiagen
Ltd.) and the mouse Fpr2 primer set (QT00171514, Qiagen).
Relative expression of the target gene was normalized to ex-
pression of the Hypoxanthine Phosphoribosyltransferase (Hprt)
gene, using the ΔΔCt method.
Statistical Analyses. Sepsis clinical score analysis was performed
using Fisher’s exact test (2 × 2 tables). Statistical differences
were determined using one- or two-way analysis of variance, as
appropriate, followed by Tukey’s posttest. A P value < 0.05 was
taken as significant for rejection of the null hypothesis.
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Fig. S1. Cell phenotype during ongoing CLP. WT and Fpr2/3−/− mice were subjected to CLP at time 0 (Methods). (A) Temporal changes in total number of cells
recruited in the peritoneal cavity post-CLP in WT and Fpr2/3−/− animals. Data are mean ± SEM of six mice per genotype. ***P < 0.001 versus respective WT value
(two-way ANOVA, post hoc Tukey test). (B) Immunofluorescent microscopic analysis of Iba1-positive cells (arrowheads) in peritoneal exudates 24 h post-CLP
fromWT and Fpr2/3−/−mice. (C and D) Cumulative data for CD3+ (T cells) and B220+ (B cells) in the peritoneal cavity post-CLP fromWT and Fpr2/3−/−mice. Data
are mean ± SEM of six mice per genotype.
Fig. S2. Fpr2/3 deficiency does not affect neutrophil recruitment for classical chemoattractants. Mice were injected i.p. with three classical neutrophil che-
moattractants (LTB4, 100 ng; TNFa, 1 μg; KC, 1 μg) or vehicle (V; 100 μL). Four hours after the injection, peritoneal lavages were collected. Cells were stained for
Ly6G or F4/80. Data are mean ± SEM of 4–5 mice per group.
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Fig. S3. Peritoneal soluble inflammatory mediator generation in Fpr2/3−/− mice during polymicrobial sepsis. WT and Fpr2/3−/− mice were subjected to CLP at
time 0 (Methods). (A–H) At 24 h post-CLP, blood was collected and plasma samples prepared and tested for cytokine levels using the cytokine bead assay by
flow cytometry. Data are mean ± SEM of six mice per group. **P < 0.01, ***P < 0.001 versus correspondent WT value (two-way ANOVA, post hoc Tukey test).
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Fig. S4. Plasma soluble inflammatory mediator generation in Fpr2/3−/−mice during polymicrobial sepsis. WT and Fpr2/3−/−mice were subjected to CLP at time
0 (Methods). (A–F) At 24 h post-CLP, blood was collected and plasma samples prepared and tested for cytokine levels using the cytokine bead assay by flow
cytometry. Data are mean ± SEM of six mice per group. **P < 0.01, ***P < 0.001 versus correspondent WT value (two-way ANOVA, post hoc Tukey test).
Fig. S5. Annexin A1 and Lipoxin A4 levels in peritoneal exudates during polymicrobial sepsis. WT and Fpr2/3
−/− mice were subjected to CLP at time
0 (Methods). (A) Annexin A1 was quantified by sandwich ELISA. Quantitative Annexin A1 levels over the time course of the CLP response. (B) Lipoxin A4 (LXA4)
was identified and quantified by LC–MS/MS-based lipidomic analysis. Quantitative LXA4 levels over the time course of the CLP response. (C) Spectrum of
relative peaks for LXA4. (D) LXA4 signature fragment ions reported asm/z, highlighting the two diagnostic fragments at 115 and 351 (351 is the ion mass). Data
are mean ± SEM of six mice. ***P < 0.001 versus correspondent WT value (two-way ANOVA, post hoc Tukey test).
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Fig. S6. Sham settings and bacterial levels in CLP. WT and Fpr2/3−/− mice were subjected to CLP at time 0 (Methods). (A) Representative flow cytometry
scattergrams illustrating bacteria (SYTO BC bacteria dye) positive events in sham peritoneal exudates from WT (Left) and Fpr2/3−/− (Right) mice. The density of
bacteria in the experimental samples was determined from the ratio of bacterial to microsphere signals. (B) Measurement of aerobic bacteria levels in peri-
toneal lavages 24 h post-CLP from WT and Fpr2/3−/− mice. Data are mean ± SEM of six mice. *P < 0.05 versus correspondent WT value (Student t test). (C)
Measurement of bacterial levels 24 h after CLP in plasma from WT and Fpr2/3−/− mice. Data are mean ± SEM of six mice. *P < 0.05 versus correspondent WT
value (Student t test).
Fig. S7. Fpr2 modulation in mouse and human cells. (A) Biogel-elicited macrophages from Fpr2/3−/− mice were incubated with sham or 24-h CLP lavages
(collected from WT or Fpr2/3−/− animals) for 24 h at 37 °C, before assessment of GFP fluorescence by flow cytometry. Data are mean ± SEM of six mice per
group. **P < 0.01, ***P < 0.001 versus correspondent sham value (two-way ANOVA, post hoc Tukey test). (B) Biogel-elicited macrophages from WT and
TNFαR1−/− mice were incubated for 24 h with 50 ng/mL TNFα before Fpr2/3 mRNA quantification by real-time PCR. Data are mean ± SEM of 4–6 distinct cell
preparations. ***P < 0.001 versus WT value (two-way ANOVA, post hoc Tukey test). (C) Zymosan-elicited PMN from Fpr2/3−/−mice were incubated for 24 h with
50 ng/mL TNFα before assessment of GFP fluorescence by flow cytometry, used as a reporter for Fpr2/3 gene promoter activity. (D) Human monocytes were
incubated for 24 h with 50 ng/mL TNFα before assessment of FPR2/ALX expression by flow cytometry. Data are mean ± SEM of 3–4 distinct cell preparations. *P <
0.05, **P < 0.01 versus control (Student t test).
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Fig. S8. Organ injury modulation between the two genotypes. WT and Fpr2/3−/−mice were subjected to CLP at time 0 (Methods). (A and B) Temporal changes
in plasma urea and creatinine post-CLP in WT and Fpr2/3−/− animals. (C and D) Temporal changes in plasma alanine aminotransferase and aspartate amino-
transferase post-CLP in WT and Fpr2/3−/− animals. (E and F) Kidney and lung MPO activity at different times post-CLP. Data are mean ± SEM of six mice. **P <
0.01, ***P < 0.001 between genotypes (two-way ANOVA, post hoc Tukey test).
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Fig. S9. Fpr2/3 agonism modulates the host response to polymicrobial sepsis. WT and Fpr2/3−/− mice were subjected to CLP at time 0 (Methods) and treated
with an AnxA1-based peptide CR-Ac2–50 1 h and 9 h postsurgery, using a dose of 90 μg/kg i.p., or with vehicle (100 μL i.p.), and killed at 24 h post-CLP. (A and B)
Plasma alanine aminotransferase and aspartate aminotransferase values in WT and Fpr2/3−/− animals. (C) Presence or absence of six different macroscopic signs
of sepsis—namely, lethargy, piloerection, tremors, periorbital exudates, respiratory distress, and diarrhea. (D–F) Cumulative data for total number of cells, Ly6G+
cells (neutrophils), and monocyte–macrophage (F4/80+ cells; Mo) counts in peritoneal exudates from WT and Fpr2/3−/− mice treated i.p. with vehicle or CR-Ac2–50.
(G) Peritoneal bacterial load. (H) CR-Ac2–50 treatment reduces exudate TNFa, compared with vehicle, in WT but not Fpr2/3
−/− mice. (I and J) CR-Ac2–50 treatment
reduces plasma TNFa and IL-6 levels, compared with vehicle, in WT but not Fpr2/3−/− mice. Data are mean ± SEM of six mice per group. *P < 0.05 versus corre-
spondent WT value (Student t test).
Table S1. Bioactive lipid mediator quantification in peritoneal exudates
Genotype Treatment PGE2, pg/mL TXB2, pg/mL
6-keto-PGF1α,
pg/mL LTB4, pg/mL PGD2, pg/mL
WT Sham 106 ± 8 62 ± 38 362 ± 85 30 ± 20 105 ± 7
CLP 12 h 426 ± 148 439 ± 70 5,229 ± 1,365 210 ± 46 13 ± 13
CLP 24 h 813 ± 258 628 ± 187 4,006 ± 11 348 ± 103 839 ± 401
Fpr2/3−/− Sham 126 ± 24 30 ± 25 346 ± 103 30 ± 18 120 ± 32
CLP 12 h 1,026 ± 382 710 ± 161 10,616 ± 2,370* 630 ± 186 48 ± 39
CLP 24 h 5,297 ± 2,257*** 1,405 ± 493 20,628 ± 5,360** 746 ± 292 2,458 ± 1,015
WT and Fpr2/3−/−mice were subjected to CLP at time 0 (Methods), with sham animals being operated without
cecum damage. Cell-free lavage fluids were analyzed by LC–MS/MS-based lipidomic analysis for multiple lipid
mediators. Data (mean ± SEM of six mice per group) are expressed as concentrations. Results are mean ± SEM of
six mice. *P < 0.05, **P < 0.01, ***P < 0.001 versus respective WT value (two-way ANOVA, post hoc Tukey test).
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